Shares of UCB SA (OTCMKTS:UCBJY – Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $93.61 and traded as high as $96.26. UCB shares last traded at $94.31, with a volume of 38,479 shares trading hands.
UCB Price Performance
The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The business has a 50 day moving average price of $97.49 and a 200 day moving average price of $93.66.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Featured Stories
- Five stocks we like better than UCB
- Why Invest in 5G? How to Invest in 5G Stocks
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- Stock Analyst Ratings and Canadian Analyst Ratings
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
